Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Relapsed Ovarian or Peritoneal Cancer
NCT00227721Phase 2Completed
- Start
- Feb 2004
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and docetaxel in ovarian epithelial cancer and primary peritoneal cancer (PPC). Primary endpoint: Response Rate up to 5 years. Started Feb 2004; status: completed.
02
Drugs
gemcitabinedocetaxel
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00227721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227721.